open access

Vol 13, No 5 (2017)
Review paper
Published online: 2017-11-15
Get Citation

Atezolizumab — PD-L1 inhibitor in non-small-cell lung cancer

Aleksandra Piórek1, Magdalena Zaborowska-Szmit1
DOI: 10.5603/OCP.2017.0029
·
Oncol Clin Pract 2017;13(5):211-215.
Affiliations
  1. Department of Lung and Thoracic Cancer, The Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw

open access

Vol 13, No 5 (2017)
REVIEW ARTICLES
Published online: 2017-11-15

Abstract

Advanced non-small-cell lung cancer is still a challenging disease. Chemotherapy and EGFR or ALK tyrosine
kinase inhibitors are well-established options. Immunotherapy with immune-checkpoint inhibitors significantly
improves survival both in first- and second-line treatment. Atezolizumab is one of the novel immunotherapies. This
paper presents current data on mechanisms of action and clinical data of atezolizumab in second-line treatment
of patients with advanced non-small-cell lung cancer.

Abstract

Advanced non-small-cell lung cancer is still a challenging disease. Chemotherapy and EGFR or ALK tyrosine
kinase inhibitors are well-established options. Immunotherapy with immune-checkpoint inhibitors significantly
improves survival both in first- and second-line treatment. Atezolizumab is one of the novel immunotherapies. This
paper presents current data on mechanisms of action and clinical data of atezolizumab in second-line treatment
of patients with advanced non-small-cell lung cancer.

Get Citation

Keywords

non-small-cell lung cancer; advanced disease; immunotherapy; atezolizumab

About this article
Title

Atezolizumab — PD-L1 inhibitor in non-small-cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 5 (2017)

Article type

Review paper

Pages

211-215

Published online

2017-11-15

DOI

10.5603/OCP.2017.0029

Bibliographic record

Oncol Clin Pract 2017;13(5):211-215.

Keywords

non-small-cell lung cancer
advanced disease
immunotherapy
atezolizumab

Authors

Aleksandra Piórek
Magdalena Zaborowska-Szmit

References (16)
  1. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017; 6(2): 196–211.
  2. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015: 76–83.
  3. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5): 765–772.
  4. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013; 73(8): 2381–2388.
  5. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004; 10(15): 5094–5100.
  6. Fehrenbacher L, Spira A, Ballinger M, et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030): 1837–1846.
  7. McLaughlin J, Han G, Schalper K, et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology. 2016; 2(1): 46.
  8. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4): 847–856.
  9. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520(7547): 373–377.
  10. Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016; 6: 20090.
  11. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017; 12(2): 208–222.
  12. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230): 124–128.
  13. Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2015; 372(21): 2018–2028.
  14. Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.
  15. Krzakowski M. Nowotwory płuca, opłucnej, śródpiersia. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia kliniczna tom II. Via Medica, Gdańsk 2015: 556–558.
  16. Kawecki M. Current literature review. Oncol Clin Pract. 2016; 12: 197–200.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl